Business ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Clinical Research Market Competition Market Trends Market Access Market Launch Market Approval Market Impact FDA Approval Weight Loss Drugs Regulatory Affairs Market Authorization Market Regulation Regulatory Approval Eli Lilly Market Analysis Market Pricing Lykos Therapeutics Pricing Strategies Psychedelic Drugs Market Potential Novo Nordisk Research and Development Regulatory Compliance Orphan Drugs Market Demand Clinical Studies FDA Approval Process Market Strategy Research Funding Tirzepatide Acquisitions ALS Treatment Alzheimer's Drug Development Liver Disease Treatment Weight-Loss Drug Development Clinical Trials Support ALS Treatments Alzheimer's Disease Drug Safety Innovative Medicines AI Integration Patent Applications Vaccine Manufacturers Global Market Access Generic Medications Manufacturing Patient Charities Vaccine Approval Market Exclusivity Legal Issues Covid Drugs Novo Nordisk and Eli Lilly Cost Reduction Strategies Regulatory Approvals COVID-19 Drugs FDA Regulations Covid-19 Vaccines Operation Warp Speed Market Authorization Holders Cost Reduction Regulatory Submissions Investment Market Performance Weight-loss Drugs Innovative Therapies Patent Disputes Regulatory Environment Biosimilar Drugs Oncology Drugs Collaborations Collaboration Licensing Agreements Oncology Semaglutide Product Launch Gene Therapy Cost Analysis Corporate Ethics Psychedelic Companies Investment in Healthcare Clinical Research Organizations Inflation Reduction Act Company Responses Weight-Loss Drugs Nirsevimab Gilead Sciences Market Dynamics Antibiotics Production Competition Market for Addiction Treatments Market Introduction Biopharmaceuticals Research Collaboration Biosimilar Launches Market Expansion Gene Therapies Karuna Therapeutics Mifepristone Ruling Antibody-Drug Conjugates

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

The company released topline, open-label results that await full review.

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Lilly Files Orforglipron Obesity Pill With FDA After Trial Shows Weight-Loss Maintenance

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

Roche’s Giredestrant Cuts Early Breast Cancer Recurrence 30% in Phase III Trial

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Bayer Stroke Drug Asundexian Hits Phase III Goals, Shares Jump

European Commission Authorizes Gobivaz, First Simponi Biosimilar, Across the EEA

FDA Names Richard Pazdur to Lead Drug Review Center

FDA Outlines 'Plausible-Mechanism' Pathway to Speed Bespoke Therapies

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises